Skip to main content
. 2021 Mar 5;95:107531. doi: 10.1016/j.intimp.2021.107531

Table 2.

Laboratory findings of severe COVID-19 patients on admission.

Normal range Median (IQR)
P Value
Nonprobioctics(n = 188) Probiotics(n = 123)
Blood biochemistry
CREA, μmol/L 57–111 63.8(53.8–76.4) 68.0(53.8–72.1) 0.088
BUN, mmol/L 2.9–8.2 4.0(1.0–4.5) 4.0(3.4–5.6) 0.183
AST, U/L 8–40 41.0(35.5–51.0) 23.0(15.0–32.0) 0.692
ALT, U/L 5–40 69.0(53.0–91.0) 19.0(13.0–41.5) 0.595
LDH, U/L 109–245 194.0(166.5–249.5) 211.0(188.0–239.5) 0.122
T-BIL, umol/L 3–20 12.5 ± 7.19 12.4 ± 5.72 0.847
Blood routine
Lymphocytes, G/L 1.1–3.2 1.1 ± 0.49 1.0 ± 0.46 0.635
HGB, g/L 40–50 122.8 ± 21.47 125.4 ± 16.30 0.254
PLT, G/L 125–350 248.8 ± 92.4 233.4 ± 92.69 0.159
WBC, G/L 3.5–9.5 5.9 ± 2.43 5.9 ± 2.43 0.858
NE, G/L 1.8–6.3 4.4 ± 2.42 4.3 ± 2.35 0.923
EO, G/L 0.01–0.52 0.07 ± 0.13 0.07 ± 0.30 0.820
Infection-related biomarkers
CRP, mg/L 0–8 2.5(1.3–2.7) 11.7(2.7–73.2) 0.077
PCT, ng/ml ≤0.05 0.05(0.03–0.05) 0.05(0.03–0.12) 0.476
ESR, mm/h 0–20 49.0 ± 30.59 63.4 ± 36.56 0.049*
IL-6 0.1–5 4.1(3.6–5.4) 8.1(5.2–12.6) 0.001**
Coagulation function
D-Dimer, mg/L 0–0.5 1.3(0.7–1.4) 0.4(0.3–1.0) 0.697
FIB, G/L 2.0–4.0 4.4 ± 1.19 4.3 ± 1.31 0.476
Immunity
Total T lymphocyte 58.17–84.22 71.8 ± 9.88 71.9 ± 8.53 0.965
CD4 25.34–51.37 42.8 ± 8.66 43.4 ± 9.01 0.750
CD8 14.23–38.95 24.95 ± 9.79 26.01 ± 8.6 0.669
B lymphocyte 4.1–18.31 13.77 ± 9.75 12.44 ± 8.33 0.462
NK cell 3.33–30.47 8.5 ± 5.24 9.8 ± 6.11 0.280
CD4/CD8 ratio 0.41–2.72 2.18 ± 1.23 2.07 ± 1.36 0.651

Data are presented as medians (interquartile ranges, IQR), n (%) and mean ± SD; *P < 0.05, **P < 0.01.

CREA, creatinine; BUN, blood urea nitrogen; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; T-BIL, total bilirubin; HGB, hemoglobin; PLT, platelets; WBC, white blood cell; NE, neutrophil; EO, eosinophilic granulocyte; CRP, c-reactive protein; PCT, procalcitonin; IL-6, interleukin 6; FIB, Fibrinogen.